PITX2 and hepatocellular carcinoma: Our findings and studies by other groups indicate that RGS acts as a RAS-mimetic that inhibits two of the major RAS-signaling pathways in HCC, i.e. MAPK- and PI3K-signaling, herewith exhibiting strong anti-tumorigenic effects (Figure 7).